Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Submits Revised Requisition for General Meeting of Shareholders Condemns Company’s Governance and Corrects the Record on Mereo’s Misleading Public Statements ... | September 14, 2022
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today,...
PolyPid's product for preventing surgical site infection failed to achieve its primary endpoint, although results for one subgroup of patients were more encouraging.
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...